Global Markets
Novartis (NOVN SW) remibrutinib delivered comprehensive disease control in a Phase 3 RMS trial
StockNow breaking-news AI analysis
The report says remibrutinib met its primary endpoint, but relapse-rate reductions were below expectations, disability progression was not significantly slowed, and Novartis shares fell as much as 4.5%.
News detail
The experimental multiple sclerosis pill met its primary endpoint but fell short of analyst expectations, Bloomberg said Relapse rates fell 35% and 31% (exp. 50%), versus 51% and 59% for Roche’s (ROG SW) rival treatment The drug also failed to significantly slow disability progression. Novartis shares fell as much as 4.5%.
Related stocks
1 stocks
What do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.